Clinical translation of nanoparticle drug (nanodrug) delivery systems for cancer therapy is primarily hindered by short half-life of nanodrugs in blood circulation and their poor ability of tumor targeting and penetration in vivo. Circulatory cells have garnered much attention in cancer therapy as drug delivery vehicles due to their biocompatibility, high mobility, biodegradability, tissue targeting capability, high drug loading capacity, ability to cross biological barriers and inherent ability to remain in blood circulation long enough to accumulate within the tumors. Here, we review the progress and potential of circulatory cells as nanodrug delivery vehicles, especially for cancer therapy.

纳米药物（na​​nodrug）递送系统用于癌症治疗的临床翻译主要受到纳米药物在血液循环中半衰期短以及它们在体内靶向和渗透的能力差的阻碍。循环细胞由于具有生物相容性，高迁移率，生物降解性，组织靶向能力，高载药量，穿越生物屏障的能力以及在血液循环中停留时间长到足以在体内积累的固有能力，因此在癌症治疗中作为药物输送载体备受关注。肿瘤。在这里，我们回顾了循环细胞作为纳米药物输送载体的进展和潜力，特别是对于癌症治疗。